×
About 3,255 results

ALLMedicine™ Progressive Supranuclear Palsy Center

Research & Reviews  1,134 results

Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerad...
https://doi.org/10.1016/j.parkreldis.2022.06.008
Parkinsonism & Related Disorders; Carlos AF, Sekiya H et. al.

Jun 26th, 2022 - Multiple system atrophy (MSA) typically presents with parkinsonism, ataxia and/or autonomic dysfunction. Occasionally, clinically atypical (ca-MSA) cases masquerade as progressive supranuclear palsy (PSP). We aimed to investigate whether different...

Genetics of validated Parkinson's disease subtypes in the Oxford Discovery and Tracking...
https://doi.org/10.1136/jnnp-2021-327376
Journal of Neurology, Neurosurgery, and Psychiatry; Lawton M, Tan MM et. al.

Jun 23rd, 2022 - To explore the genetics of four Parkinson's disease (PD) subtypes that have been previously described in two large cohorts of patients with recently diagnosed PD. These subtypes came from a data-driven cluster analysis of phenotypic variables. We ...

Morphometric imaging and quantitative susceptibility mapping as complementary tools in ...
https://doi.org/10.1111/ene.15447
European Journal of Neurology; Mazzucchi S, Del Prete E et. al.

Jun 15th, 2022 - In the quest for in vivo diagnostic biomarkers to discriminate Parkinson's disease (PD) from progressive supranuclear palsy (PSP) and multiple system atrophy (MSA, mainly p phenotype), many advanced magnetic resonance imaging (MRI) techniques have...

Investigational therapeutics for the treatment of progressive supranuclear palsy.
https://doi.org/10.1080/13543784.2022.2087179
Expert Opinion on Investigational Drugs; Coughlin DG, Litvan I

Jun 14th, 2022 - Progressive supranuclear palsy (PSP) is a progressive neurodegenerative disease marked by a variety of movement, ocular, and cognitive symptoms. Currently, treatment is symptomatic, and there are no disease-modulating therapies. While clinical pre...

Neuropathology and emerging biomarkers in corticobasal syndrome.
https://doi.org/10.1136/jnnp-2021-328586
Journal of Neurology, Neurosurgery, and Psychiatry; Koga S, Josephs KA et. al.

Jun 14th, 2022 - Corticobasal syndrome (CBS) is a clinical syndrome characterised by progressive asymmetric limb rigidity and apraxia with dystonia, myoclonus, cortical sensory loss and alien limb phenomenon. Corticobasal degeneration (CBD) is one of the most comm...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  107 results

Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy
https://clinicaltrials.gov/ct2/show/NCT04468932

May 17th, 2022 - The objective of this proposal is to investigate the effect of non-invasive repetitive cerebellar transcranial magnetic stimulation (rTMS) on motor control in progressive supranuclear (PSP). The central hypothesis is that augmenting cerebellar inh...

Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)
https://clinicaltrials.gov/ct2/show/NCT04014387

Apr 29th, 2022 - Prior research has identified profound sleep disruption in individuals with PSP. Not only were these individuals sleeping relatively short periods at night, they were also not recuperating lost sleep during the day. Research also showed the relati...

DaTSCAN Imaging in Aging and Neurodegenerative Disease
https://clinicaltrials.gov/ct2/show/NCT01453127

Apr 29th, 2022 - Lewy body disease (LBD) is one of the most common neurodegenerative diseases and second only to Alzheimer's disease in terms of prevalence, disability, and societal/financial burden. The phenotypic variability of LBD is striking, as it can manifes...

A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP
https://clinicaltrials.gov/ct2/show/NCT04008355

Apr 26th, 2022 - A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy. The patient study duration is 29 weeks i...

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
https://clinicaltrials.gov/ct2/show/NCT04993768

Apr 25th, 2022 - This is a Phase 2a multi-center, randomized, double-blind, placebo-controlled parallel-group, 4-arm study with an open-label treatment phase in patients with PSP. This study includes a 6-week Screening Period, a 24-week Double-blind Treatment Peri...

see more →

News  52 results

Tau Moderated by Menopause; CTE Risk Underestimated; When Is a Single Study Enough?
https://www.medpagetoday.com/neurology/generalneurology/98523

May 3rd, 2022 - Menopause status moderated sex differences in tau burden, with a divergence in tauopathy between the sexes apparent 20 years earlier than previously reported. (Annals of Neurology) Plasma p-tau was a less consistent marker of brain amyloidosis in ...

Blood Biomarkers May Distinguish Dementia Disorders
https://www.medpagetoday.com/neurology/dementia/96915

Jan 28th, 2022 - Blood-based biomarkers may help differentiate people with different dementias and monitor disease changes over time, a longitudinal study showed. Plasma markers showed different profiles in Alzheimer's disease, frontotemporal dementia, Lewy body d...

Alzheimer's Blood Test Predicts Pathology
https://www.medpagetoday.com/neurology/alzheimersdisease/90555

Jan 6th, 2021 - This story was published originally on May 4, 2020. As part of MedPage Today's review of stories in the past year, we're republishing it, along with an update on further developments in blood tests for Alzheimer's disease. An ultrasensitive blood ...

Blood biomarker may predict Parkinson’s disease progression
https://www.mdedge.com/neurology/article/228309/parkinsons-disease/blood-biomarker-may-predict-parkinsons-disease
Jim Kling

Sep 10th, 2020 - A novel biomarker could help identify progression in Parkinson’s disease, distinguish it from other neurodegenerative disorders, and monitor response to treatments. Although the biomarker, neurofilament light chain (NfL), is not especially specifi.

Negative Phase 2 Trial Data Ends Development of PSP Drug
https://www.medscape.com/viewarticle/922592

Dec 13th, 2019 - Topline results from the phase two PASSPORT trial show the experimental drug gosuranemab (BIIB092, Biogen) did not meet its primary or key secondary endpoints in patients with the atypical parkinsonian disorder of progressive supranuclear palsy (P...

see more →

Patient Education  7 results see all →